Research and Markets: The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/156b6d/the_future_of_glob) has announced the addition of the "The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis" report to their offering.

By 2016, the Global Vaccines Market is Expected to Generate More Than Twice the Annual Revenue of 2009

The global vaccines industry was valued at $24 billion in 2009 and is expected to reach $52 billion in 2016 at a Compounded Annual Growth Rate (CAGR) of 11.5%. The vaccines market, which was once considered a low-profit segment of the top players' portfolios, showed a turnaround after the resounding success of Prevnar, the first blockbuster vaccine. The ability of vaccines to generate high revenue and profits despite being priced at a premium has proven attractive to both existing players in the market and to big pharmaceutical companies who have been watching the development of the market with interest.

The surge in revenues and growth rates came at a time when the pharmaceutical industry was under huge pressure from patent expiries and weakened pipelines. The pharmaceutical industry has been intent on strengthening their revenue streams and streamlining operations through lay-offs and shutdowns of manufacturing and R&D operations. The success of premium priced vaccines such as Prevnar, Gardasil, and Cervarix has prompted big pharmaceutical players such as Pfizer and AstraZeneca to invest in the vaccines industry which promises safe revenues due to a lack of threat from generics.

The Vaccines Industry is Looking to Increase its Revenues Through the Introduction of Novel Vaccines and Indication Expansions for Established Products

The authors analyze that the market dynamics in the current vaccines industry reflects a shift towards a functional model that is characteristic of the conventional pharmaceutical industry. A number of innovative vaccines are in development and have been introduced which have focused on product differentiation as a means to success. The influenza vaccines market has a number of vaccines which are considered commodities due to a lack of differentiation. However, companies are using new vaccine technologies in an effort to increase the prices and increase profits from the segment. Also, vaccine players are looking to utilize the brand equity of successful vaccines in generating more revenues from a disease segment. Vaccines such as Prevnar and Gardasil, which are generating more than $1 billion a year, are being extended for preventing more related diseases with the aim of adding to the existing revenue streams. Prevnar, which is a 7-valent vaccine, preventing against seven serogroups, is being developed as Prevnar-13 to prevent against an additional six serogroups. Gardasil, which was originally approved for the prevention of four strains of human papillomavirus, is now being developed for the prevention of nine strains. Product extension strategies which are commonplace in the pharmaceutical industry are now being used extensively in the vaccines industry to benefit from the existing popularity of a successful brand. The vaccines industry is expected to use lifecycle management strategies to full effect in order to retain and improve revenues from their portfolio.

Licensing and Alliance Agreements Accounted for 81% of the M&A and Licensing Landscape

The authors analyze that licensing and co-development agreements are characteristic of the global vaccines market where technologies and development platforms are highly dispersed amongst small and big companies. Smaller vaccine companies that do not have the financial muscle to compete against the top vaccine players make use of their technologies to generate revenues through royalties and through other revenue sharing agreements. Also, a number of public-private partnerships help the vaccines industry develop interventions for new diseases

The global vaccines industry is a difficult industry for smaller companies to succeed in due to the high development costs required for licensing, acquisitions, marketing and manufacturing. Vaccine companies with promising candidates in the pipeline engage in out-licensing agreements with the top players, who in turn provide marketing, sales, and regulatory support. However, the vaccines industry remains an attractive one for large and small companies alike due to its potential to generate revenues from smaller disease populations too. Hence, the vaccines industry is expected to remain highly active in the future fuelled by the encouragement and financing from governments and other health organizations.

The scope of this report includes:

  • Annualized market data for the global vaccines market from 2000 to 2008, forecast forward to 2015.
  • Analysis of the metabolic disorder therapeutics market in the leading geographies of the world. This includes the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization data on the global vaccines market including market size, market share and annual cost of vaccination.
  • Key drivers and restraints that have a significant impact on the market
  • Competitive landscape of the global vaccines market. The key companies studied in this report are Novartis AG, Sanofi Pasteur, Merck & Co, GlaxoSmithKline and Pfizer Inc.
  • Key M&A activities and licensing agreements that have taken place between 2008 and 2009 in the global vaccines market.

Reasons to buy

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficiency and better safety.

Key Topics Covered:

  • Introduction
  • Research Report Guidance
  • The Future of Global Vaccines : Market Overview
  • The Future of Global Vaccines: Global Vaccines Market
  • The Future of Global Vaccines: The US Vaccines Market
  • The Future of Global Vaccines: European Vaccines Market
  • The Future of Global Vaccines: Rest of the World
  • The Future of Global Vaccines: Global Rotavirus Vaccines Market
  • The Future of Global Vaccines: Global Pneumococcal Vaccines Market
  • The Future of Global Vaccines: Global Human Papillomavirus Vaccines Market
  • The Future of Global Vaccines: Global Seasonal Flu Vaccines Market
  • The Future of Global Vaccines: Competitive Landscape
  • The Future of Global Vaccines : Strategic Consolidations
  • Appendix

Companies Mentioned:

  • Novartis AG
  • Sanofi Pasteur
  • Merck & Co
  • GlaxoSmithKline
  • Pfizer Inc.

For more information visit http://www.researchandmarkets.com/research/156b6d/the_future_of_glob

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716